Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lumiracoxib.

Katherine A Lyseng-Williamson1, Monique P Curran

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|October 1, 2004
PubMed
Summary
This summary is machine-generated.

Lumiracoxib effectively reduces pain and improves function in osteoarthritis and acute pain conditions. It demonstrates a favorable safety profile, with fewer gastrointestinal issues than traditional NSAIDs and no increased cardiovascular events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020
Same author

Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2020
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same author

Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Drug Development
  • Clinical Trials

Background:

  • Lumiracoxib is a selective cyclo-oxygenase (COX)-2 inhibitor with unique properties.
  • Understanding its efficacy and safety in various pain conditions is crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of lumiracoxib in patients with osteoarthritis and acute pain.
  • To compare lumiracoxib's performance against placebo, nonselective NSAIDs, and other COX-2 inhibitors.

Main Methods:

  • Conducted well-designed clinical trials of 1-52 weeks duration for osteoarthritis and acute pain indications.
  • Administered oral lumiracoxib at doses ranging from 100-800 mg/day.
  • Compared outcomes with placebo, nonselective NSAIDs, celecoxib, and controlled-release oxycodone.

Related Experiment Videos

Main Results:

  • Lumiracoxib demonstrated superior efficacy over placebo in reducing pain and improving function in osteoarthritis and acute pain.
  • Its efficacy was comparable to nonselective NSAIDs and other selective COX-2 inhibitors.
  • Lumiracoxib showed a significantly lower rate of gastrointestinal ulcer complications compared to ibuprofen and naproxen.
  • No increased cardiovascular events were observed with lumiracoxib use.

Conclusions:

  • Lumiracoxib is an effective treatment for osteoarthritis and acute pain.
  • It offers a favorable gastrointestinal safety profile compared to traditional NSAIDs.
  • Lumiracoxib presents a safe and effective therapeutic option with no associated cardiovascular risks.